Website
News25/Ratings4
News · 26 weeks30-25%
2025-10-262026-04-19
Mix1490d
- Insider6(43%)
- Other6(43%)
- SEC Filings2(14%)
Latest news
25 items- PRNextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary
- PRNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026 BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an
- PRNextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ongoing open-label, Phase 1 s
- SECSEC Form 10-K filed by NextCure Inc.10-K - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsData readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2025 financial results. "2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505, in deve
- SECAmendment: SEC Form SCHEDULE 13D/A filed by NextCure Inc.SCHEDULE 13D/A - NextCure, Inc. (0001661059) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.SCHEDULE 13G/A - NextCure, Inc. (0001661059) (Subject)
- INSIDERSEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Sr VP, Dev. & Mfg. Kundu Sourav4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Richman Michael4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Mayer Timothy4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Guha Udayan4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Cobourn Steven P.4 - NextCure, Inc. (0001661059) (Issuer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business UpdateSIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose escalation data expected in Q2 2026SIM0505 is a novel ADC directed to cadherin-6 (CDH6 ADC), which is overexpressed in several cancers with limited expression in healthy tissues. SIM0505 features a
- SECNextCure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form 424B5 filed by NextCure Inc.424B5 - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form EFFECT filed by NextCure Inc.EFFECT - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form 424B1 filed by NextCure Inc.424B1 - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form D filed by NextCure Inc.D - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form S-3 filed by NextCure Inc.S-3 - NextCure, Inc. (0001661059) (Filer)
- PRNextCure to Present at the Piper Sandler 37th Annual Healthcare ConferenceBELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3rd, at 11:00 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company
- SECNextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data ReadoutsExtends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept ("POC") data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management in a private placement of common stock priced at the market BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced the closing of its previously announced private placement in public equity ("PIPE"). The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare F